Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236847 | 0.85 | SMN1; SMN2 (0.48) | FFAR1SMN1; SMN2TDP1ALDH1A1PPARA | |
| SCHEMBL2948148 | 0.85 | FFAR1 (0.68) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2947981 | 0.85 | SMN1; SMN2 (0.74) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2949666 | 0.84 | FFAR1 (0.62) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2948910 | 0.83 | FFAR1 (0.54) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2939675 | 0.82 | FFAR1 (0.64) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2941508 | 0.82 | MMP9 (0.65) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2946000 | 0.82 | FFAR1 (0.60) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL13264702 | 0.81 | FFAR1 (0.71) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 | |
| SCHEMBL2949131 | 0.81 | MMP9 (0.67) | FFAR1SMN1; SMN2POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | claimed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | claimed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176912-A1 | GPR40 AGONISTS | GPR119, GPR65, GPR55 | FFAR1 8/4885SMN1; SMN2 3652/4885POLB 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.